In the past few years, the market for cancer therapies and technologies has come a long way. Not so long ago, cancer posed many obstacles to investors including long development time lines to validate new science, prolonged regulatory pathways to demonstrate survival, and small, niche markets for drugs with limited efficacy in narrow patient populations. But all that is changing. There have been several heartening success stories in the field—the colorectal cancer drug cetuximab (Erbitux), for example, caused its developer, ImClone Systems Inc. to become the object of a bidding war, won in October 2008 by Eli Lilly & Co. The winning bid was $6.5 billion. [See Deal] (See "Eli Lilly’s Oncology Focus," IN VIVO, October 2008 Also see "Eli Lilly's Oncology Focus" - In Vivo, 1 October, 2008..)
Cancer is replacing cardiovascular disease as the large, underserved disease of aging (and an enormous, underserved market), judging by the actions of some of the largest companies in health care....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?